China Money Network
Login
Join

Vivo Capital, OrbiMed Lead $80M Series B Round In Biopharmaceutical Start-Up Terns Pharmaceuticals

  • October 31, 2018 — 11:10 CST

This Data Is Locked!

This area is available only to Subscribers.

Terns Pharmaceuticals, a US and Shanghai-based biopharmaceutical start-up, has raised US$80 million in series B round of financing led by Vivo Capital and OrbiMed. New... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: